Alnylam Pharmaceuticals said this week that it has extended its lipid delivery-technology collaboration with the University of British Columbia and Canadian firm AlCana Technologies for a third year.
The research collaboration is funded by Alnylam and the work will be conducted by scientists at UBC and AlCana.
Under the terms of the research alliance, which was forged in 2009, Alnylam has the exclusive rights to all new inventions in the RNAi field, as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners.
As part of the original agreement, Tekmira Pharmaceuticals receives the rights to use any new AlCana/UBC inventions for its own RNAi therapeutic programs licensed under Alnylam intellectual property.